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We present a prospective observational study of Gram-negative bacteremia. MALDI-
TOF allowed an early adaptation of 35% of empirical antibiotic treatments and had a 
more frequent impact than Gram stain reporting. 
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Abstract  
Background: 
Early identification of pathogens from blood cultures using matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry (MALDI-TOF) may optimize the 
choice of empirical antibiotic therapy in the setting of bloodstream infections. We aimed 
to assess the impact of this new technology on the use of antibiotic treatment in patients 
with Gram-negative bacteremia. 
 
Methods:  
We conducted a prospective observational study from January to December 2010 to 
evaluate the sequential and separate impacts of Gram stain reporting and MALDI-TOF 
bacterial identification performed on blood culture pellets in patients with Gram-negative 




Among 202 episodes of Gram-negative bacteremia, Gram stain reporting had an impact 
in 42 cases (20.8%). MALDI-TOF identification led to a modification of empirical therapy 
in 71 of all 202 cases (35.1%), and in 16 of 27 cases (59.3%) of monomicrobial 
bacteremia caused by AmpC-producing Enterobacteriaceae. The most frequently 
observed impact was an early appropriate broadening of the antibiotic spectrum in 31 of 
71 cases (43.7%). In total, 143 of 165 episodes (86.7%) of monomicrobial bacteremia 
were correctly identified at genus level by MALDI-TOF. 
 
Conclusions:  
In a low prevalence area for extended spectrum betalactamases (ESBL) and multi-
resistant Gram-negative bacteria, MALDI-TOF performed on blood culture pellets had 
an impact on the clinical management of 35.1% of all Gram-negative bacteremia cases, 
demonstrating a greater impact than Gram stain reporting. Thus, MALDI-TOF could 
become a vital second step beside Gram stain in guiding the empirical treatment of 
patients with bloodstream infection.  
Introduction 
 
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF), formerly confined to research laboratories, has emerged as a recent revolution in 
clinical microbiology.1 For bacterial identification, this technology compared favourably 
with the classical phenotypical methods in bacteriology in terms of time to result, 
accuracy, ease of use and cost-effectiveness.2,3 Due to the speed of this technology, 
MALDI-TOF was very soon applied to identify microorganisms detected in blood 
cultures,4-6 since an appropriate antibiotic therapy covering the etiological agent is of 
paramount importance in decreasing mortality of bacteremic patients with sepsis.7,8 In 
the setting of bloodstream infections, MALDI-TOF applied to bacterial pellet obtained 
from positive blood culture is allowing a rapid identification of around 80% of pathogens.  
This identification is accurate in ≥ 99% of cases.4-6 Identification of Gram-negative 
pathogens has been shown to be very reliable, although the success rate is lower for 
Gram-positive bacteria (mainly streptococci) and for encapsulated bacteria such as 
Klebsiella pneumoniae and Haemophilus influenzae.4-6 
 
In clinical practice, the microbiology laboratory has an impact on the management of 
bloodstream infections at first by reporting the results of positive blood cultures. Munson 
et al. demonstrated that the Gram stain result reported by telephone to the clinician had 
an even greater influence on the antibiotic regimen than antimicrobial susceptibility 
testing.9 A same-day transmission of MALDI-TOF-based identification of the pathogen 
isolated from blood cultures would obviously represent another opportunity to increase 
the appropriateness of empirical antibiotic therapy. Although this strategy is theoretically 
promising, very few data are available analysing the routine use of MALDI-TOF in this 
setting.10, 11  
 
The aim of our study was thus to assess the impact of MALDI-TOF on the clinical 
management of Gram-negative bacteremia. We prospectively performed MALDI-TOF 
MS-based bacterial identification on blood culture pellets immediately after Gram stain 
reporting5 and assessed the impact of this procedure on antimicrobial treatment. 
 Methods 
Design and case definition: 
This prospective observational study was conducted between January and December 
2010 in the University Hospital of Lausanne, an 850-bed primary and tertiary care 
hospital in Western Switzerland. Patients with a first episode of Gram-negative 
bacteremia (including polymicrobial infections) for whom an infectious diseases (ID) 
consultation was performed were included (figure 1). Data on successive antibiotic 
therapies were prospectively assessed by the clinical microbiologist when reporting the 
results to the clinicians using a standardized case report form (CRF). The sequence of 
antibiotic prescription was checked using the ID consultation report and a final CRF was 
filled in to include standardized clinical and epidemiological data. The impact of the 
Gram stain (first step) and the MALDI-TOF reporting (second step) on the antimicrobial 
management were assessed by two ID specialists (O.C and G.G) as described below. 
The primary outcomes were the respective and separate impacts of each step on the 
empirical antibiotic therapy. The design of this study was in accordance with the ethical 
standards of our local ethics committee. 
 
Routine procedures 
Positive blood cultures were detected by the BACTEC 9240 automated blood culture 
system (Becton Dickinson, Sparks, MD). The microbiology laboratory ran daily from 8 
AM to 17 PM. Gram stain was immediately performed on all positive blood cultures 
during this period, and early the next morning when the blood cultures became positive 
overnight. Direct MALDI-TOF has been routinely performed in our center since 
September 2009 on all positive blood cultures immediately after the Gram staining. 
According to local procedure, pellets from positive blood cultures were prepared as 
described by Prod’hom et al.5 during the same day when bacterial growth was detected 
before 17 PM. Under these circumstances, Gram stain reporting was followed about 
one hour later by a second call to the clinician in charge of the patient in order to 
transmit the MALDI-TOF-based identification.  
Mass spectra were acquired on a Microflex LT MALDI-TOF (Bruker Daltonics, Bremen, 
Germany). Spectral analysis and comparison with the database were performed using 
MALDI BioTyper 2.0 software. According to the criteria proposed by the manufacturer, 
an identification was considered reliable at the species level when the score value was 
x ≥ 2 and at the genus level when the score was 1.7 ≤ x < 2. Blood culture results were 
transmitted by clinical microbiologists directly to the clinicians and during a daily 




The incidence of Gram-negative bacteria producing extended spectrum betalactamases 
(ESBL) was low according to the hospital microbiology database (< 5% of all Gram-
negative bacilli). Similarly, community-associated ESBL-producing Escherichia coli 
remained rare in 2010 (3.4%, source: www.anresis.ch). Carbapenemase-producing 
organisms were not documented during the study period. As a consequence, third 
generation cephalosporins were the empirical first choice for non-AmpC-producing 
Enterobacteriaceae except in previously known ESBL carriers and in patients with 
severe sepsis or neutropenia, where broad spectrum antibiotic treatments were 
considered adequate. Fourth generation cephalosporins or carbapenems were chosen 
when AmpC-producing Enterobacteriaceae were detected. Our local antibiotic policy 
was summarized in local consensus guidelines developed by ID specialists and based 
on local epidemiology. These guidelines did not support the use of quinolones as 
empirical therapy.  
Study definitions 
Polymicrobial bacteremia was defined as the isolation of > 1 microorganism during the 
same bacteremic episode, except when the second microorganism was a coagulase-
negative staphylococci (generally considered as a contaminant). A previous ESBL 
carriage was recorded according to the hospital infection control database. 
Immunosuppression included HIV infection and specific medications (prednisone 
equivalent ≥ 5 mg/d, cancer chemotherapy, TNFα inhibitors and other 
immunosuppressive drugs). Penicillin allergy was included as stated in the medical 
record regardless of stage/gravity of the presumed reaction. A bacteremia was 
considered hospital-acquired if blood cultures were taken ≥ 48h after hospitalization. 
Neutropenia was defined as an absolute neutrophil cell count < 0.5 x 109 neutrophils/L. 
Severe sepsis and septic shock were defined according to standard definitions.12 
Streamlining was defined as the reduction of the antibiotic spectrum, either after Gram 
staining or after MALDI-TOF reporting, as for instance, the interruption of a specific anti-
Gram-positive coverage of vancomycin when only Gram-negative pathogens were seen 
on the blood culture Gram stain. Similarly, spectrum broadening was defined after one 
of the two steps when the antibiotic coverage changed toward a broader spectrum. For 
instance, spectrum broadening occurred following MALDI-TOF reporting of 
Enterobacter cloacae, changing empirical therapy from ceftriaxone to cefepime. Gram 
stain could lead to the introduction of an empirical antibiotic therapy. MALDI-TOF 
reporting allowed the introduction of a focused empirical antibiotic therapy as for 
instance, the introduction of an initial treatment with cefepime in case of the early 
detection of E. cloacae.  
 
Statistics 
Categorical variables were compared using the chi-square or Fisher’s exact tests when 
appropriate; continuous variables were compared using the Mann-Whitney test. 
Analyses were conducted using the GraphPad Prism software version 5.03 (GraphPad 





There were 202 first episodes of Gram-negative bacteremia leading to an ID 
consultation during the study period (figure 1), among which 37 (18.3%) were 
polymicrobial and 120 (59.4%) were hospital-acquired. Main sources of infection were 
the digestive tract in 69 cases (34.2%), the urinary tract in 65 cases (32.2%) and 
intravascular catheters in 26 cases (12.9%) (Table 1). 
 
Among the 242 episodes of Gram-negative bacteremia that were excluded as they did 
not lead to an ID consultation (figure 1 and supplementary table), 100 (41.3%) were 
diagnosed in the emergency department. Enterobacteriaceae were the more frequently 
identified class, with 207 episodes (85.5% of all), among which were 146 cases of E. 
coli bacteremia. AmpC-producing bacteria were found in 23 cases (9.5% of all) and 
non-fermentative bacteria in 15 cases (6.2%).  
 
Pathogens and identification scores (Table 2) 
Among the 202 episodes of Gram-negative bacteremia, 37 (18.3%) were polymicrobial 
and 165 (81.7%) were monomicrobial. Altogether, 143 of 165 episodes of 
monomicrobial bacteremia (86.7%) were correctly identified with a score ≥ 1.7. Among 
the 37 episodes of polymicrobial bacteremia, at least one pathogen could be reliably 
identified at the genus level in 28 cases (75.7%). Nevertheless, a correct identification 
at the genus level of all pathogens in a given polymicrobial blood culture was only 
possible in 11/37 cases (29.7%). 
 
Among the 165 episodes of monomicrobial bacteremia, Enterobacteriaceae were 
documented in 120 cases (59.4%). MALDI-TOF identification performed on the blood 
culture pellet confirmed a high reliability for this bacterial family since 117 of all 
Enterobacteriaceae (97.5%) were correctly identified with a score ≥ 1.7. All 27 AmpC-
producing Enterobacteriaceae species (13.4%) were correctly identified at the genus 
level.  
 
Non-fermentative bacteria were documented in 25/202 cases, representing 12.4% of all 
cases. Pseudomonas spp. were identified in 9 out of 22 cases (40.9%), whereas the 
other three non-fermentative bacteria were all correctly identified at species level.  
 
Impact of Gram stain and MALDI-TOF reporting  
The sequential impact of Gram stain and MALDI-TOF identification reporting on 
empirical antibiotic therapy are summarized in figure 2. Overall, Gram stain reporting 
had an impact in 42 cases (20.8% of all 202 Gram-negative bacteremia). Despite a 
positive impact of Gram stain, MALDI-TOF reporting further influenced the treatment in 
8/42 cases (19%). When Gram stain had no impact, MALDI-TOF reporting led to a 
modification of empirical antibiotic therapy in 63/160 cases (39.4%). Altogether, MALDI-
TOF had an impact on empirical therapy in 71 cases (35.1% of all 202 bacteremia 
cases). The most frequent impact of MALDI-TOF was an early appropriate broadening 
of the antimicrobial spectrum (table 3). MALDI-TOF had an impact on 16/27 episodes 
(59.3%) of monomicrobial bacteremia caused by AmpC-producing Enterobacteriaceae, 
whereas an impact was documented in only 39/93 cases (41.9%) of other 
Enterobacteriaceae. MALDI-TOF had an impact in only 8/37 episodes (21.6%) of 
polymicrobial bacteremias, in only 6/25 episodes (24%) of monomicrobial bacteremia 
with non-fermentative bacteria and had no impact in the four previously known ESBL 
carriers. Impact of Gram stain reporting in cases of polymicrobial bacteremias (12/37, 
32.4%) was greater than that of MALDI-TOF MS. 
 
Among the 131 cases where the MALDI-TOF did not lead to treatment modification, an 
impact would have been possible in 31 cases but no modification occurred. Factors 
associated with lack of modification of empirical antibiotic therapy are shown in table 4. 
Among these, intensive care unit (ICU) acquisition of bacteremia was associated with 
the absence of consideration of MALDI-TOF result, as were the male sex and younger 
age. Adaptation of antibiotic treatment was more likely for patients presenting with 
urosepsis (P = 0.06). 
 
Discussion 
In this prospective, single-arm observational study including 202 episodes of Gram-
negative bloodstream infections, we observed that MALDI-TOF reporting had an impact 
on antibiotic therapy in 35.1% of bacteremia, whereas Gram stain had an impact in 
20.8% of cases. In addition, we confirmed the excellent reliability of MALDI-TOF for 
bacterial identification on blood culture pellets outside of validation studies,4-6 in the real-
life setting of routine microbiology practice. As previously reported, the reliability of this 
new technology was especially high for Enterobacteriaceae.4-6 A maximal impact was 
observed when AmpC-producing Enterobacteriaceae were documented, given their 
particular pattern of antibiotic resistance. As already published,4,13 we documented a 
lower reliability of MALDI-TOF in cases of polymicrobial bacteremia, a situation where 
the Gram stain result is more informative. Thus, this justifies always performing direct 
Gram staining examination of any positive blood cultures even in the MALDI-TOF era. 
 
Reducing the time to result in clinical microbiology has been achieved using various 
approaches and aims (i) to impact on the clinical outcome of patients, (ii) to optimize the 
use of antibiotics and (iii) to reduce costs.14-17 Gram stain reporting is part of routine 
management of bloodstream infections, as it has been shown to have the greatest 
impact on antimicrobial empirical therapy.9 Improvement in Gram stain turnaround time 
has even been associated with a decrease in patient mortality.18 Indeed, as early 
appropriate antibiotic therapy has been shown to reduce the mortality of bloodstream 
infections,19 there is an obvious need for techniques which could increase initial 
antibiotic appropriateness. Although there has been numerous publications in the recent 
years on the additional value of bacterial identification with MALDI-TOF in blood 
cultures,4-6,13,20 there are few data on the clinical impact of this new strategy to justify its 
implementation in routine practice. Vlek et al. compared two sequential periods in a 
prospective study: one standard period during which only Gram staining and results of 
susceptibility testing could influence the antibiotic therapy, and one intervention period 
in which MALDI-TOF was added to study its possible impact on empirical treatment. 
Among 253 episodes of bacteremia, 89 led to MALDI-TOF identification with an early 
correct identification in 56.2% of episodes. The application of MALDI-TOF increased the 
proportion of appropriate treatments within 24 hours of blood cultures positivity by 
11.3%.10 Hodiamont et al. recently presented unpublished data showing that the 
addition of MALDI-TOF identification to Gram stain reporting led to an early adaptation 
of antibiotic therapy in up to 29% of 73 cases of bloodstream infection.11 Both studies 
came from the Netherlands where the incidence of antimicrobial resistance remains low. 
Our data from a country with low but increasing ESBL prevalence are in line with these 
two studies. 
 
Our study has limitations. Its single arm, observational design precluded us from 
evaluating the impact of MALDI-TOF on the clinical outcome of patients as, in our 
hospital, MALDI-TOF has been included in the routine management of blood cultures 
since we initially validated this approach5. We included only cases managed with the 
help of an ID consultation, as these were clinically the most relevant and as the 
resulting report allowed us to obtain precise information regarding the sequence of 
antibiotic therapy. The overrepresentation of non-AmpC-producing Enterobacteriaceae 
(mostly E. coli) in the 242 cases that were excluded and the predominance of 
ambulatory cases in that group, suggest that among these 242 cases, there were more 
common infections such as urosepsis, for which the impact of MALDI-TOF identification 
might be less important and might be managed without the need of an ID consultation. 
However, this study design corresponds to the routine clinical management of Gram-
negative bacteremia in our hospital and probably in many others. In this sense, we think 
that our results are useful to estimate the true benefits of this new technology in a real-
life setting. Our study was conducted in a low prevalence area for ESBL and for multi-
resistant Gram-negative bacteria, which could possibly lead to an overestimation of the 
impact of MALDI-TOF MS. Finally, prescription of an empirical antibiotic therapy is a 
complex decision involving epidemiological considerations, severity of disease and 
experience or education of the clinician in charge, as suggested by the determinants of 
the effective impact of MALDI-TOF MS. The impact of MALDI-TOF may thus vary 
according to the epidemiological setting, the site where bacteremia was managed 
(particularly ICU) or the presumed site of infection. Indeed, clinicians might feel more 
comfortable with the early identification of bacteria using an unfamiliar technology if the 
urinary tract was the suspected source of bacteremia, as uropathogens might be more 
predictable than pathogens from a suspected catheter infection. Further studies 
including educational approaches might help to target these hypotheses. 
 
The main strength of our study is that we document the clinical application of MALDI-
TOF performed directly on blood culture pellets as well as its successful implementation 
in routine clinical microbiology. Indeed, we observed that this new technology had an 
impact in more than one third of all episodes of Gram-negative bacteremia. Although 
these findings should be confirmed by larger, randomized studies including clinical 
outcomes, our data suggest that rapid MALDI-TOF MS-based identification of bacteria 
grown from blood cultures could become a second critical step in the management of 
patients with positive blood cultures besides Gram stain reporting. 
 
 
 Figures legends: 
Figure 1: Selection of patients (ID = infectious diseases) 
Figure 2: Sequential impact of Gram stain and MALDI-TOF identification on empirical 
antibiotic therapy. Cases that benefited from MALDI-TOF are highlighted in dark grey. 
  
Table 1: Characteristics of the 202 cases of Gram-negative bacteremia 
included in the study. 
 
 
Characteristics N = 202 
Male sex  122 (60.3) 
Age (mean, years) 62 
Previous ESBL carriage 4 (2.0) 
Immunosuppression 62 (30.7) 
Agranulocytosis 9 (4.5) 
Severe sepsis/septic shock 28 (13.9) 
History of penicillin allergy 11 (5.4) 
Hospital-acquired bacteremia 120 (59.4) 
ICU acquisition 23 (11.4) 
Polymicrobial bacteremia 37 (18.3) 
Sources of bacteremia  
Digestive tract 69 (34.2) 
Urinary tract 65 (32.2) 
Catheter infection 26 (12.9) 
Respiratory tract 10 (5.0) 
Other source 25 (12.4) 
Unknown 7 (3.5) 
 
 
Data are presented as n (%), unless stated otherwise. 
Abbreviation: ICU = intensive care unit.  
 Table 2: Types of pathogen and identification scores  
 
 
Pathogens N = 202 Score > 2 1.7<= score < 2 Score < 1.7 
Enterobacteriaceae 120 (59.4)    
Escherichia coli 56 (27.7) 53 3 - 
Klebsiella spp. 25 (12.4) 18 4 3 
Enterobacter spp. 18 (8.9) 15 3 - 
Citrobacter freundii 1 (0.5) 1 - - 
Citrobacter koseri 4 (2.0) 4 - - 
Serratia spp. 5 (2.5) 5 - - 
Proteus spp. 8 (4.0) 8 - - 
Morganella spp. 2 (1.0) 2 - - 
Hafnia alvei 1 (0.5) - 1 - 
Non-fermentative 25 (12.4)    
Pseudomonas spp 22 (10.9) 5 4 13 
Acinetobacter spp 1 (0.5) 1 - - 
Stenotrophomonas spp 2 (1.0) 2 - - 
Other aerobic  8 (4.0)    
Salmonella spp 4 (2.0) 2 1 1 
Haemophilus spp 3 (1.5) 1 - 2 
Campylobacter spp 1 (0.5) 1 - - 
Anaerobes 12 (5.9)    
Bacteroides spp 7 (3.5) 3 3 1 
Other  5 (2.5) - 1 4 
Polymicrobial (best identification) 37 (18.3) 26 2 9 
 
Data are presented as n (%) 
 
 
 Table 3: Impact of sequential Gram stain and MALDI-TOF reporting 
 
 
Impact of the sequential reporting N = 202 
Gram stain  42 (20.8) 
Streamlining 16 (7.9) 
Spectrum broadening 16 (7.9) 
Introduction of empirical antibiotic therapy  10 (5.0) 
MALDI-TOF MS 71 (35.1) 
Streamlining 22 (10.9) 
Spectrum broadening 31 (15.3) 
Introduction of focused empirical antibiotic therapy 18 (8.9) 
 
























Data are n (%), unless stated otherwise. 
Abbreviations: ICU = intensive care unit, n.a = not applicable 
 
 
Characteristics Impact  
N = 71 
Possible impact 
N = 31 
P value 
Male sex  45 (63.4) 6 (19.4) < 0.0001 
Age (mean, years) 65.8 61.2 < 0.0001 
Previous ESBL carriage 0 0 n.a. 
Immunosuppression 17 (23.9) 9 (29.0) 0.63 
Agranulocytosis 0 1 (3.2) 0.30 
Severe sepsis/septic shock 9 (12.7) 3 (9.7) 1.00 
History of penicillin allergy 3 (4.2) 2 (6.5) 0.64 
Hospital-acquired bacteremia 43 (60.6) 22 (71.0) 0.37 
ICU acquisition 1 (1.4) 9 (29.0) < 0.0001 
Polymicrobial bacteremia 8 (11.3) 1 (3.2) 0.27 
Source of bacteremia    
Urinary tract 26 (36.6) 5 (16.1) 0.06 
Digestive tract 19 (26.8) 14 (45.2) 0.11 
Catheter infection 12 (16.9) 3 (9.7) 0.54 
Unknown 3 (4.2) 0 0.55 
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Supplementary table: Characteristics of the 242 cases of Gram-negative 
bacteremia that were excluded. 
 
 
Characteristics N = 242 
Male sex  126 (52.1) 
Age (mean, years) 52* 
Diagnosed in emergency ward 100 (41.3)* 
Enterobacteriaceae 207 (85.5)* 
Escherichia coli 146 (60.3)* 
Klebsiella spp. 28 (11.6) 
Proteus spp. 7 (2.9) 
AmpC-producers 23 (9.5) 
Non-fermentative 15 (6.2)* 
Pseudomonas spp. 12 (5.0) 
Other aerobic bacteria 8 (3.3) 
Anaerobes 11 (4.5) 
Polymicrobial bacteremia 0 (0)* 
 
 
Data are presented as n (%), unless stated otherwise.  
* indicates p < 0.05 vs. included cases. 
 
 
